{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06467435",
            "orgStudyIdInfo": {
                "id": "94519"
            },
            "organization": {
                "fullName": "University of Kentucky",
                "class": "OTHER"
            },
            "briefTitle": "Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)",
            "officialTitle": "Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "evaluation-of-in-subjects-with-thyroid-eye-disease-ted"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-14",
            "studyFirstSubmitQcDate": "2024-06-14",
            "studyFirstPostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-28",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Peter Timoney",
                "investigatorTitle": "Associate Professor",
                "investigatorAffiliation": "University of Kentucky"
            },
            "leadSponsor": {
                "name": "Peter Timoney",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Inflammasome Therapeutics",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The objective of this clinical trial is to evaluate the plasma pharmacokinetics of K9 in healthy subjects (Cohort 1) and the safety and treatment efficacy of K9 in patients with active Thyroid Eye Disease (Cohort 2). Participants will receive study medication one time or for up to 4 weeks. Participants will have blood drawn and/or complete eye exams and questionnaires.\n\nThe planned duration of this study is 6 weeks."
        },
        "conditionsModule": {
            "conditions": [
                "Thyroid Eye Disease"
            ],
            "keywords": [
                "Kamuvudine-9",
                "K9"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 8,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Patients with Thyroid Eye Disease (TED)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive a regimen of 96 mg tablets of K9 twice a day for 4 weeks",
                    "interventionNames": [
                        "Drug: Kamuvudine-9"
                    ]
                },
                {
                    "label": "Healthy Volunteers",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive one dose of 96 mg tablets of K9 based on weight",
                    "interventionNames": [
                        "Drug: Kamuvudine-9"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Kamuvudine-9",
                    "description": "96 mg tablets taken twice a day for 4 weeks",
                    "armGroupLabels": [
                        "Patients with Thyroid Eye Disease (TED)"
                    ],
                    "otherNames": [
                        "K9"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Kamuvudine-9",
                    "description": "96 mg tablets taken once",
                    "armGroupLabels": [
                        "Healthy Volunteers"
                    ],
                    "otherNames": [
                        "K9"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse Events",
                    "description": "Frequency of participants experiencing ocular or systemic adverse events.",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "plasma concentrations of K9",
                    "description": "plasma concentrations measured after a single oral dose in healthy adults. For each of these time points 5 ml of blood will be drawn.",
                    "timeFrame": "Pharmacokinetic samples collected pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, and 24 hours after dosing"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in Standardized Patient Evaluation of Eye Dryness (SPEED) symptoms",
                    "description": "The SPEED Questionnaire will be used to track progression of dry eye symptoms. The SPEED questionnaire has eight questions. The frequency and severity of symptoms are rated on a numeric scale. Scores range from 0 to 28 with higher scores equating to more symptoms.",
                    "timeFrame": "Baseline (Day 1) and weeks 1, 4, and 6"
                },
                {
                    "measure": "Change in Diplopia",
                    "description": "Diplopia is assessed by the Bahn-Gorman Scale. The Bahn-Gorman scale is a subjective grading scheme that uses a scale of 0-3 to assess the severity of diplopia. A higher score equates to more severe diplopia.",
                    "timeFrame": "Baseline (Day 1) and weeks 1, 4, and 6"
                },
                {
                    "measure": "Change in Study Visit in Clinical Activity Score (CAS),",
                    "description": "Clinical Activity Score (7 point scale) with higher score equating to more symptoms",
                    "timeFrame": "Baseline (Day 1) and weeks 1, 4, and 6"
                },
                {
                    "measure": "Change in proptosis",
                    "description": "Hertel exophthalmometry will be used to measure the globe position of the eye by calculating the distance from the lateral orbital rim to the surface of the cornea in millimeters (mm)",
                    "timeFrame": "Baseline (Day 1) and weeks 1, 4, and 6"
                },
                {
                    "measure": "Change in Graves' ophthalmopathy-specific quality-of-life scale (GO-QOL)",
                    "description": "The GO-QOL is a self-administered health-related QOL questionnaire specifically designed and validated in patients with TED. It includes 2 subscale GO-QOL scores: (1) visual functioning and (2) appearance-related, with the 2 weighted equally to create an overall score. Both the subscales and overall score are transformed to a scale of 0 to 100, 0 indicating worst health and 100 indicating best health.",
                    "timeFrame": "Baseline (Day 1) and weeks 1, 4, and 6"
                },
                {
                    "measure": "Change in upper eyelid retraction",
                    "description": "upper eyelid retraction will be determined by measuring the margin reflex distance (MRD1) in millimeters. The MRD1 is the measurement in millimetres from the light reflex on the patient's cornea to the level of the centre of the upper eyelid margin, with the patient gazing in the primary position.",
                    "timeFrame": "Baseline (Day 1) and weeks 1, 4, and 6"
                },
                {
                    "measure": "Change in lower eyelid retraction",
                    "description": "Lower eyelid retraction is measured by the distance from the inferior limbus to the lower eyelid, or by the margin reflex distance 2 (MRD2). The distance between the corneal light reflex to the central portion of the lower eyelid is measured in millimeters",
                    "timeFrame": "Baseline (Day 1) and weeks 1, 4, and 6"
                },
                {
                    "measure": "Change in inflammasome output cytokines IL-1B",
                    "description": "measured by ELISA",
                    "timeFrame": "Baseline (Day 1) and weeks 1, 4, and 6"
                },
                {
                    "measure": "Change in inflammasome output cytokines IL-18",
                    "description": "measured by ELISA",
                    "timeFrame": "Baseline (Day 1) and weeks 1, 4, and 6"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nCohort 1\n\n* Subject is willing and able to receive treatment and complete corresponding assessments as required by the protocol\n\nCohort 2\n\n* Diagnosed with Thyroid Eye Disease (TED).\n* Symptomatic TED diagnosed no more than 9 months earlier.\n* Clinical Activity Score \u2265 3 (on 7 point scale) for the worse eye.\n* Subject is willing and able to receive treatment and complete corresponding assessments as required by the protocol.\n\nExclusion Criteria:\n\nCohort 1\n\n* Body weight less than 55 kg.\n* History of any clinically significant medical disorders the principal investigator considers exclusionary, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease.\n* Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception.\n* History or current evidence of hypersensitivity to any components of the study medication, as assessed by the investigator.\n* Participation in any systemic experimental treatment or any other systemic investigational new drug within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of study treatment. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary\n\nCohort 2\n\n* Body weight less than 55 kg.\n* Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception.\n* History or current evidence of hypersensitivity to any components of the study medication, as assessed by the investigator.\n* Participation in any investigational drug or ocular device study within 30 days prior to the Day 1 Study Visit.\n* History or current evidence of a medical condition that may, in the opinion of the investigator, preclude the safe administration of study medication or affect the results of the study.\n* Participation in any systemic experimental treatment or any other systemic investigational new drug within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of study treatment. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary.\n* History of use of teprotumumab (Tepezza), radiotherapy, or orbital surgery.\n* History (last 6 weeks) of use of systemic (oral, intravenous, or intramuscular) corticosteroids or immunosuppressants (e.g. mycophenolate), intravenous immunoglobulin, or plasmapheresis.\n* Clinical activity score \\< 3\n* Uncontrolled diabetes or hypertension\n* History of mental / psychiatric disorder\n* Hepatic dysfunction (Albumin (Alb), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline phosphates levels must be within normal range for eligibility)\n* Renal impairment (Urea, Creatinine, and Glomerular Filtration Rate levels must be within normal range)\n* Any baseline condition that the principal investigator considers exclusionary.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Connie Dampier",
                    "role": "CONTACT",
                    "phone": "859-562-0750",
                    "email": "dampier@email.uky.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Peter Timoney",
                    "affiliation": "University of Kentucky",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Kentucky",
                    "city": "Lexington",
                    "state": "Kentucky",
                    "zip": "40506",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Connie Dampier",
                            "role": "CONTACT",
                            "phone": "859-562-0750",
                            "email": "dampier@email.uky.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.98869,
                        "lon": -84.47772
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                },
                {
                    "id": "D000049970",
                    "term": "Graves Ophthalmopathy"
                },
                {
                    "id": "D000013959",
                    "term": "Thyroid Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000015785",
                    "term": "Eye Diseases, Hereditary"
                },
                {
                    "id": "D000006111",
                    "term": "Graves Disease"
                },
                {
                    "id": "D000005094",
                    "term": "Exophthalmos"
                },
                {
                    "id": "D000009916",
                    "term": "Orbital Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000006042",
                    "term": "Goiter"
                },
                {
                    "id": "D000006980",
                    "term": "Hyperthyroidism"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16718",
                    "name": "Thyroid Diseases",
                    "asFound": "Thyroid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "asFound": "Eye Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26148",
                    "name": "Graves Ophthalmopathy",
                    "asFound": "Thyroid Eye Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M18339",
                    "name": "Eye Diseases, Hereditary",
                    "relevance": "LOW"
                },
                {
                    "id": "M9214",
                    "name": "Graves Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M8237",
                    "name": "Exophthalmos",
                    "relevance": "LOW"
                },
                {
                    "id": "M12845",
                    "name": "Orbital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M9147",
                    "name": "Goiter",
                    "relevance": "LOW"
                },
                {
                    "id": "M10031",
                    "name": "Hyperthyroidism",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                }
            ]
        }
    },
    "hasResults": false
}